Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Anesthesia type doesn't change cancer surgery outcomes, study finds. A meta-analysis of nearly 8,000 patients found that propofol-based and volatile-based anesthesia produce equivalent long-term results in curative cancer surgery. No significant differences were seen in overall survival, recurrence-free survival, or cancer recurrence rates between the two approaches.
Anesthesia type doesn't change cancer surgery outcomes, study finds
A new meta-analysis published in Anaesthesia addresses a long-debated question: does the type of anesthesia used during cancer surgery affect patient outcomes? Researchers analyzed 11 randomized controlled trials involving 7,811 adults undergoing curative or potentially curative cancer surgery, comparing propofol-based total intravenous anesthesia against volatile inhalational agents.
The results were consistent across every major outcome measured — both approaches performed equally well in terms of overall survival, recurrence-free survival, postoperative mortality, and cancer recurrence. Minimal variability across studies (I² = 0%) and a high GRADE certainty rating lend strong confidence to these conclusions.
By the Numbers:
Why it matters: Clinicians have long speculated that propofol may offer immunoprotective benefits over volatile agents in cancer surgery. This high-certainty evidence suggests anesthesiologists can choose between the two based on other clinical factors — without concern about compromising long-term cancer outcomes.
